This notion is support by breast cancer patients who experienced tumor progression after treatment with trastuzumab (Herceptin, Genentech), a monoclonal antibody targeted against HER2, have demonstrated responses to the dual EGFR and HER2 tyrosine kinase inhibitor lapatinib (Tykerb, GSK) [20]. Here, ERBB2 is linked to neoplasm.